Oryzon Genomics (MC:ORY)’ public listing in Madrid puts this rapidly emerging epigenetic player on the map in a highly promising yet still uncrowded technology space. Oryzon has advanced its lead compound ORY-1001 to a Phase I/IIa trial in acute leukaemia patients and we expect initial efficacy data around the end of 2016. Oryzon is a rare pure-play in epigenetics, with Roche already on board, and now trades at a relatively modest EV of €96m.
To read the entire report Please click on the pdf File Below